hc-7366
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2022 (NCT05121948)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EIF2AK4 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06285890 | Phase 1 | May 20, 2024 | HiberCell, Inc., University of Texas at Houston |
| NCT06234605 | Phase 1 | Apr 29, 2024 | HiberCell, Inc., Merck |
| NCT05121948 | Phase 1 | Jan 31, 2022 | Covance, HiberCell, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HiberCell, Inc. | For profit | 3 | 2 | 1 | 2022 |
| Covance | For profit | 1 | 0 | 1 | 2022 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1